Ardelyx Reports Q3 2026 Revenue Growth Driven by IBSRELA and XPHOZAH Demand
Ardelyx (ARDX) reported strong third-quarter 2026 financial results, with total product revenue reaching $125.5 million, a 19% increase year-over-year. This growth was primarily fueled by IBSRELA, which saw a 23% revenue rise to $96.3 million, and XPHOZAH, which grew 7% despite sequential fluctuations caused by customer inventory patterns. The company successfully narrowed its net loss to $700,000 from $1 million in the prior year period. Management is leveraging high gross profit margins (over 95%) to fund clinical pipeline development, including the ACCEL Phase III trial, and aims for profitability by 2027. Strategic investments include a direct-to-consumer marketing campaign reaching 10 million people via streaming platforms.
Tickers: $ARDX
Topics: financial guidance net loss reduction product performance revenue growth